Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer. Background: Approximately 35% of HER2-amplified ...
New ARCHITECT plasma pro-gastrin-releasing peptide assay and lung cancer: Implications for diagnosis, follow-up, and prognosis. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results